xe 991 dihydrochloride (Bio-Techne corporation)
Bio-Techne corporation is a verified supplier 
Bio-Techne corporation manufactures this product 
99
Structured Review
Bio-Techne corporation
xe 991 dihydrochloride
Xe 991 Dihydrochloride, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1199 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xe+991+dihydrochloride/XE+991+dihydrochloride/custom%402000%4042447969
Average 99 stars, based on 1199 article reviews
Xe 991 Dihydrochloride, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1199 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xe+991+dihydrochloride/XE+991+dihydrochloride/custom%402000%4042447969
Average 99 stars, based on 1199 article reviews
xe 991 dihydrochloride - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Imaging:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Incubation:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Virus:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Clone Assay:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Generated:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Software:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Saline:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Fat:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, Purification:Article Title: Corticostriatal glutamate mechanisms underlying beta synchrony and motor deficits via striatal NMDA receptors in Parkinson’s disease Article Snippet: re delivered at 80 nL/min via a Hamilton syringe. After 3–4 weeks for viral expression, chemogenetic manipulation was induced with intraperitoneal clozapine N-oxide (CNO; 3 or 10 mg/kg, Cat. No. 4936, |